TScan Therapeutics Announces Executive Retention Program for CEO, CLO

What Happened

• TScan Therapeutics, Inc. filed an 8‑K reporting that on September 8, 2026 its Compensation Committee approved a retention program to keep key employees, including CEO Gavin MacBeath, Ph.D., and Chief Legal & Strategy Officer Zoran Zdraveski, JD, Ph.D. The program provides cash awards and potential equity-based awards under the company’s Amended and Restated 2021 Equity Incentive Plan.

Key Details

• Cash awards: $822,000 for CEO Gavin MacBeath and $416,000 for CLO Zoran Zdraveski.
  • Each cash award is split in half: the first half is payable partly in November 2026 and February 2027 (one‑third of the first half in Nov 2026 and two‑thirds of the first half in Feb 2027); the second half is payable upon achievement of a Clinical Milestone tied to advancement of the company’s in vivo solid tumor program.
  • For example, MacBeath’s first half is $411,000 (split $137,000 in Nov 2026 and $274,000 in Feb 2027); Zdraveski’s first half is $208,000 (approximately $69,333 in Nov 2026 and $138,667 in Feb 2027).
• Equity awards (to be granted under the 2021 Plan): 2,400,000 restricted stock units (RSUs) for MacBeath and 1,050,000 RSUs for Zdraveski.
  • Vesting: one‑third of each RSU award vests upon a Financing Milestone; the remaining two‑thirds vest in equal installments on the first and second anniversaries of the Financing Milestone, subject to continued service and plan terms.
• Approval date: Compensation Committee approved the program on September 8, 2026; disclosed in the 8‑K filed September 11, 2026.

Why It Matters

• The company is using cash and equity incentives to retain senior leaders during key development and financing activities, tying substantial payout components to clinical and financing milestones.
• Investors should note potential near‑term cash outflows (initial cash payments in Nov 2026 and Feb 2027) and the possibility of equity dilution if the RSUs are granted and vest.
• Vesting and final payout depend on achievement of specified milestones and continued service, so actual impact will hinge on clinical progress and successful financing events.